


PHARMACEUTICAL 2018



INTEGRATED BIOPHARMA INC Rank 273 of 342





PHARMACEUTICAL 2018



INTEGRATED BIOPHARMA INC Rank 273 of 342

The relative strengths and weaknesses of INTEGRATED BIOPHARMA INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of INTEGRATED BIOPHARMA INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 208% points. The greatest weakness of INTEGRATED BIOPHARMA INC is the variable Other Expenses, reducing the Economic Capital Ratio by 185% points.

The company's Economic Capital Ratio, given in the ranking table, is -43%, being 89% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	12,551
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,155
Liabilities, Non-Current	4,246
Other Assets	1,044
Other Compr. Net Income	0
Other Expenses	39,797
Other Liabilities	5,724
Other Net Income	-1,331
Other Revenues	46,954
Property and Equipment	1,601
Research and Development	0
Selling, General and Administrative Expense	3,480

Output Variable	Value in 1000 USD
Assets	15,196
Liabilities	21,125
Expenses	43,277
Revenues	46,954
Stockholders Equity	-5,929
Net Income	2,346
Comprehensive Net Income	2,346
Economic Capital Ratio	-43%

